Drug Trial Radar · NCT01294163
Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery
Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
509
Actual
Start
Apr 2011
Primary completion
Apr 2014
Study completion Apr 2014
Sponsor
- Lead sponsor
- Air Liquide Santé InternationalIndustry
- Sponsor type
- Industry
- Collaborators
- Orion Corporation, Orion Pharma
- First posted
- Feb 11, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Xenon is a gaseous anaesthetic agent registered in several European countries. It has been administered safely during cardiac surgery in pilot studies. In animal studies, xenon decreases the size of experimental myocardial infarction. This 3-arm study will compare xenon, sevoflurane and a propofol-based total intravenous anaesthesia for maintenance of anaesthesia during coronary artery bypass graft surgery conducted with extra-corporeal circulation. Xenon and sevoflurane will be administered before and after extracorporeal circulation. Propofol will be administered during extracorporeal circulation in the three groups of patients. The study will compare the postoperative myocardial damage observed 24 hours after surgery from blood levels of troponin I, a largely accepted biomarker of myocardial necrosis. The main hypothesis is that the myocardial damage observed after xenon administration will not be superior to the damage observed after sevoflurane administration (non-inferiority). The second hypothesis is that the myocardial damage observed after xenon administration will be inferior to the damage observed after total intravenous anaesthesia.
Conditions
- Coronary Artery Disease
- General Anesthetic Drug Allergy
- Coronary Artery Bypass Graft Surgery
Interventions
XenonDrug
Inhaled xenon, maximal inspired concentration of 65%.
SevofluraneDrug
Inhaled sevoflurane, maximal inspired concentration of 1.8%.
PropofolDrug
Hourly dose of 2-4 mg/kg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blood Level of Troponin ITime frame: Sampling performed 24 hours after the end of the surgical procedure
- Log-transformed Blood Level of Troponin ITime frame: Sampling performed 24 hours after the end of the surgical procedure
Locations
17 sites in 4 countries. Site status is shown where the registry gives one.
Hôpital Cardiovasculaire et Pneumologique Louis Pradel
Bron, France
CHU de Caen
Caen, France
Hôpital G&R Laennec - Centre Hospitalier Universitaire de Nantes
Nantes, France
Centre Hospitalo-Universitaire Pitié-Salpetrière
Paris, France
Hôpital du Haut-Lévêque
Pessac, France
Hôpital Pontchaillou
Rennes, France
Hôpitaux Universitaires de Strasbourg - Nouvel Hôpital Civil
Strasbourg, France
Centre Hospitalier de Rangueil
Toulouse, France
University Hospital Aachen
Aachen, Germany
Klinikum Links der Weser - Senator-Wessling-Str. 1
Bremen, Germany
University Hospital Frankfurt AM Main
Frankfurt, Germany
UniversitatsKlinikum Schleswig-Holstein
Lübeck, Germany
University Hospital ROSTOCK
Rostock, Germany
Universitätsklinikum Schleswig-Holstein
Kiel, Schleswig-Holstein, Germany
Policlinico Umberto I
Rome, Italy
Academic Medical Center - University of Amsterdam
Amsterdam, Netherlands
Thorax Center - Erasmus MC
Rotterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.